Product Specifications, Storage, and Quality Standards Analytical and Composition Specifications Active components: CJC1295 (with DAC), Ipamorelin, and GHRP-2 in a combined 2mg research-grade lyophilized blend Purity: Each component verified at minimum 98% by HPLC analysis with mass spectrometric identity confirmation Endotoxin testing: LAL assay confirmed below 1 EU/mg for the complete blend Sterility: Produced under aseptic manufacturing conditions with microbiological testing prior to release Certificate of Analysis: Provided with every batch confirming identity, purity, and safety parameters for all three components Storage, Reconstitution, and Handling Store lyophilized blend at -20 degrees Celsius, protected from light and humidity prior to reconstitution Reconstitute with sterile bacteriostatic water or sterile saline for research use use gentle swirling rather than vigorous shaking to preserve peptide integrity Reconstituted solution stability: Use within 28 days when stored at 2 to 8 degrees Celsius Avoid repeated freeze-thaw cycles which may compromise the structural integrity and biological activity of the peptide components Handle under appropriate aseptic conditions consistent with research-grade biological peptide protocols throughout all stages of use Research Use and Regulatory Statement CJC1295, Ipamorelin, GHRP-2 (Blend) 2mg is supplied exclusively for in vitro and in vivo scientific research by qualified investigators operating under appropriate institutional and regulatory oversight
Personalized guidance is important before starting any injectable treatment
Yes, GLP-1 medications were approved by the Food and Drug Administration in 2005, but today, they're more refined and gaining popularity in the news, especially among people with type 2 diabetes
We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) with GLP-1 Receptor Agonists (RAs) in patients with and without chronic kidney disease (CKD)
